Anika Therapeutics, Inc.
ANIK· Nasdaq
ANIKAnika Therapeutics, Inc.
Released Nov 5, 2025, before the open
10-Q filed Nov 5, 2025, 36 days after period end · 0001171843-25-007032
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $27.82M | $29.56M | $41.47M | $40.26M |
| Net Income | -$2.33M | -$29.92M | -$6.58M | -$4.18M |
| EPS Diluted |
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
| -$0.16 |
| -$2.03 |
| -$0.45 |
| -$0.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
